Acute Myeloid Leukaemia
The research of Dr Panoskaltsis focuses on the study of acute myeloid leukaemia (AML), its associated disorders and their immune pathology.
1. Normal dendritic cells (DC) initiate immune responses by presenting antigens to T cells. We can generate DC from leukaemic cells in AML (AML-DC) for use as anti-leukaemia vaccines
Although AML-DC resemble their normal DC counterparts, the signals they give to T-cells may be inappropriate. We have developed robust techniques to assess the potential of patients to develop anti-leukaemia immune responses.
In contrast to the blood of healthy individuals, that of AML patients contains cytokine-active lymphocytes directed towards a cytotoxic response. Ongoing research is focused on the immune pathology in AML, and the role of DC in leukaemogenesis.
2. Within the Department of Chemical Engineering, a novel three-dimensional culture system has been developed that more closely mimics the in vivo bone marrow microenvironment. This bioreactor provides a biomimetic environment for the study, propagation and expansion of normal and pathologic haemopoietic elements. Ongoing collaborative research is focused on improving the scaffold construct, stem/progenitor cell expansion and differentiation and the development of long-term culture systems for haemopoietic cells from both healthy individuals and those with diseases of the bone marrow, particularly AML.
Leukaemia Research Trust Fund